Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess.

Current vascular pharmacology·2023
Same author

Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency.

Current vascular pharmacology·2023
Same author

Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.

Digestive diseases and sciences·2021
Same author

Multifocal arterial disease: clinical implications and management.

Current opinion in cardiology·2020
Same author

Preface.

Current vascular pharmacology·2018
Same author

Daylight saving time and myocardial infarction: should we be worried? A review of the evidence.

European review for medical and pharmacological sciences·2018

Related Experiment Video

Updated: Jul 7, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Cilostazol for peripheral arterial disease.

P Robless1, D P Mikhailidis, G P Stansby

  • 1Yong Loo Lin School of Medicine, National University of Singapore, Dept of Cardiac, Thoracic and Vascular Surgery, 5 Lower Kent Ridge Road, Singapore, Singapore, 119074. surrpa@nus.edu.sg

The Cochrane Database of Systematic Reviews
|February 7, 2008
PubMed
Summary

Cilostazol improves walking distance for peripheral arterial disease patients with intermittent claudication (IC). This medication offers benefits for IC symptoms without increasing cardiovascular events or mortality.

More Related Videos

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

Related Experiment Videos

Last Updated: Jul 7, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Peripheral arterial disease (PAD) is prevalent, particularly in older adults.
  • Intermittent claudication (IC), a common PAD symptom, significantly increases cardiovascular mortality.
  • Risk factor modification, exercise, and antiplatelet therapy can improve IC symptoms and outcomes.

Purpose of the Study:

  • To evaluate cilostazol's efficacy in enhancing walking distance.
  • To assess cilostazol's impact on reducing vascular mortality and cardiovascular events in stable IC patients.

Main Methods:

  • Systematic review and meta-analysis of double-blind, randomized controlled trials.
  • Searched specialized databases including Cochrane CENTRAL, MEDLINE, and EMBASE.
  • Included trials comparing cilostazol (various doses) against placebo or other antiplatelet agents.

Main Results:

  • Cilostazol significantly improved initial claudication distance (ICD) at doses of 100 mg and 50 mg twice daily compared to placebo.
  • A trend towards increased ICD was observed with cilostazol 150 mg twice daily.
  • No significant increase in major adverse events, cardiovascular events, or mortality was associated with cilostazol use.

Conclusions:

  • Cilostazol demonstrates a clear benefit in improving walking distance for patients with intermittent claudication.
  • Secondary cardiovascular prevention remains crucial for all IC patients.
  • Further data is needed to determine cilostazol's effect on reducing adverse cardiovascular events.